Amit Bharara, MD
Pulmonary Disease · Schaumburg, ILNPI 1255567962
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $90,882 of the $100,490 with a category attached, or 90.4%. Sanofi accounts for 97.5% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $98,197, more than ten times the $158 reported in 2019. Among pulmonary disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $587.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$98K
- GSK$834
- AstraZeneca$450
- Boehringer Ingelheim$302
- Regeneron Healthcare Solutions, Inc.$168
- Boston Scientific$131
- plus $590 from 12 others
What the payments were for
- Consulting fees$1,5812%
- Speaking & faculty fees$90,88290%
- Travel & lodging$4,0004%
- Food & beverage$4,0274%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 62 | $98,015 |
| GSK | 42 | $834 |
| AstraZeneca | 14 | $450 |
| Boehringer Ingelheim | 14 | $302 |
| Regeneron Healthcare Solutions, Inc. | 5 | $168 |
| Boston Scientific | 1 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $116 |
| Electromed, Inc. | 7 | $78 |
| Sunovion Pharmaceuticals Inc. | 5 | $76 |
| Mylan Specialty L.p. | 3 | $55 |
| Mallinckrodt Hospital Products Inc. | 2 | $46 |
| Philips North America LLC | 3 | $46 |
| Harmony Biosciences LLC | 2 | $43 |
| Genentech USA, Inc. | 2 | $41 |
| Baxter Healthcare | 1 | $35 |
| Shionogi Inc | 1 | $21 |
| United Therapeutics Corporation | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$100,490 in reported general payments places this provider in the 95th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 88 | $75,928 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $33,552 |
| Breo ElliptaFluticasone/Vilanterol | 68 | $28,489 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $15,515 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $13,504 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $8,203 |
| Advair HfaFluticasone Propion/Salmeterol | 21 | $8,029 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $6,811 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $5,558 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 138 | $4,482 |
| Roflumilast | 12 | $4,133 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $3,033 |
| Zafirlukast | 51 | $2,637 |
| Ventolin HfaAlbuterol Sulfate | 18 | $1,001 |
| Azithromycin | 86 | $675 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $834 | $125,490202 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $450 | $47,05679 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Schaumburg
- Neeraj DesaiSchaumburg$48K
- Douglas HogarthChicago$2.9M
- Steven WhiteChicago$970K
- Momen WahidiChicago$779K
- Septimiu MurguChicago$633K
- Ayodeji AdegunsoyeChicago$561K
- Kristopher McDonoughJoliet$461K
- Ravi KalhanChicago$375K
- Brian GaribaldiChicago$356K
- Danish ThameemChampaign$353K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.